A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)

Trial Profile

A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs MLE 4901 (Primary)
  • Indications Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Sponsors Millendo Therapeutics
  • Most Recent Events

    • 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society
    • 03 Apr 2017 Treatment arms has changed from 4 to 2 and planned patient number has changed from 220 to 130, hence protocol amended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top